Daily Archives: May 22, 2021

Last November, Oregon became the first state to legalize psilocybin for therapeutic use. Psilocybin mushrooms, also known as magic mushrooms, are in a pilot program in Oregon where they can be used to treat depression, addiction, anxiety, and other mental health disorders. Though Texas is still in theprocess of expandingthe diagnoses that can be treated with medicinal marijuana, experts think psychedelics could follow the same pattern that marijuana cleared over the past couple of decades.

Research has shown promising results for psilocybin mushrooms, which grow in meadows and woods worldwide, in treating PTSD and depression. In May 2019, Denver became the first city to decriminalize the substance and was followed by Oakland, California, Cambridge, Massachusetts, and elsewhere. The substance was made illegal through federal law in 1970, but in 2000, Johns Hopkins was grantedaccessto study its use in treating addiction, depression, and PTSD.

Momentum is building behind the decriminalization and eventual legalization of psychedelics. Canada has also made psilocybinavailableto those with mental health issues, and psychedelics have even received theattentionofShark Tankco-host Kevin OLeary, chairman of OShares ETFs. Publicly traded companies are raising billions of dollars in the space. Wall Street estimates put the number of potential patients in the U.S. at two to four million people with annual sales from $1 to $5 billion.

Calum Hughes (Courtesy: Allied Corp.)

Investment excitement aside, broader use of psychedelics will necessitate a change in public opinion as well. Those in the space are focused on shifting the image of psychedelics from one of young people losing their mind in the streets tripping on magic mushrooms. This is a micro-dose of psilocybin that has enough therapeutic effect in the human neurons to impact adrenaline which causes anxiety, says Calum Hughes, CEO and Founder of Allied Corp., a Canadian-based health and technology company that operates in the psilocybin and marijuana markets. The product is not a magic mushroom, but is a highly complex medically researched molecule that does something very specific in the human brain.

The pandemic has meant an increase in mental health issues in an already overwhelmed industry, and these medicines may be able to impact ways that traditional drugs havent. Given COVID-19, the amount of people recovering from, experiencing, or witnessing trauma, anxiety, or social isolation is going to be even more prevalent, Hughes says. Youre talking millions and millions of people globally who are suffering from these conditions. There are a lot of antidepressant medications that are global, multibillion-dollar products. Were finding results as good or better than these products in our preliminary research. So, to say that were excited is an understatement.

Dallas may be years behind the likes of Oregon and Canada when it comes to legalizing medicinal psilocybin, but there are local efforts to decriminalize the drug in the works.Attorney and former City Council member Philip Kingston has been working in Dallas with a national group called Decriminalize Nature, whose mission is To improve human health and well-being by decriminalizing and expanding access to entheogenic plants and fungi through political and community organizing, education, and advocacy. He is helping the organization get psilocybin to be treated like marijuana in Dallas by decriminalizing small amounts of the drug.

Two years ago, Dallas County District Attorney announced he would stop prosecuting marijuana possession charges. Still, it was only this year when new police chief Eddie Garciasaidhis officers would stop charging residents with less than two ounces of marijuana. Those under four ounces will receive a ticket but not be arrested. The district attorneys office has not prosecuted 3,161 cases from January 2019 through June 2020.

Part of the advocacy for the decriminalization of psychedelics is to demonstrate the drugs medical benefits, Kingston says. This idea of decriminalization, or even legalization, came in large part because of the amazing success of substances like these on PTSD, which is an incredibly difficult syndrome to treat for the medical profession. It looks like hallucinogens might be a real breakthrough.

He is hopeful that local efforts can make progress where the state legislature has not. Nobody can stop cities from making it a policy that their officers do not arrest for these kinds of offenses, Kingston says. And nobody can make the district attorney prosecute. Thats the local breakthrough that weve achieved on this specific topic in the naturally occurring hallucinogens.

When the new council is installed later this summer after the remaining runoffs, Kingston says Decriminalize Nature will step up its advocacy efforts to decriminalize hallucinogens, which is often a step toward medicinal or full legalization. Understanding that there is no serious risk of harm from using these drugs and that there are potential medical benefits from it is the main hurdle to getting movement on it, Kingston says. Weve been encouraged that Chief Garcia has said that the focus of his department is going to be on preventing and punishing crimes that endanger Dallasites, and drug possession doesnt fall into that category.

Follow this link:

What Will Psychedelics Mean for the Future of Medicine? - D Healthcare Daily

NEW YORK, May 21, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, Wall Street Unicorns in Process of Changing the Healthcare Landscape.

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit:https://nnw.fm/QOAcO

Most people may not recognize some of the medical terms for psychedelics, but nearly all know their street names, including magic mushrooms, ecstasy, Molly and LSD. Over decades, people have been conditioned to the stigma of these illicit substances, instigated and promoted by the Controlled Substances Act. However, the negative stigma is being lifted and being replaced by a growing body of scientific clinical evidence that strongly suggests psychedelics may well become one of the greatest advancements in mental health and neuropsychiatric disease in decades. . . .

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) offers a best-in-class, drug development team capable of taking compounds from early stage and advancing them through the rigors of clinical development to commercialization. This team of executives and advisors cannot go understated as its made up of deep experience and key leadership positions throughout, including large pharma, emerging pharma, drug approvals, psychedelics and capital markets.

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryps psilocybin-for-neuropsychiatric disorders, or PFN(TM) (PFN), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryps lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status.

For more information about the company, please visitwww.TrypTherapeutics.com.

NOTE TO INVESTORS:The latest news and updates relating to TRYP are available in the companys newsroom athttps://ibn.fm/TRYPF.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2)NetworkNewsBreaksthat summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in todays market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text STOCKS to 77948 (U.S. Mobile Phones Only)

For more information please visithttps://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)New York, New Yorkwww.NetworkNewsWire.com212.418.1217 OfficeEditor@NetworkNewsWire.com

NetworkNewsWire is part of theInvestorBrandNetwork

The rest is here:

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Brings Best-in-Class Team to Psychedelics Development - BioSpace

By Brent Furdyk.18 May 2021 6:54 PM

Kristen Bell is revealing shes begun experimenting with psychedelics as a way to treat the depression and anxiety that have plagued her for decades.

Appearing on the Hypochondriactor podcast, hosted by Will & Grace star Sean Hayes and Dr. Priyanka Wali, Bell explained that she decided to take this new approach to managing her mental health after reading Michael Pollans book How to Change Your Mind.

He really goes into detail about this underground academic community that has continued to study the effects of LSD and psilocybin on what they call healthy normal, said Bell. There are aspects to those two particular drugs that the places you can go in your brain are much deeper and more healing than anything else.

RELATED: Dax Shepard Honours Kristen Bell On Mothers Day With Nude Photo: We Are So Grateful

As a result, she explained, she became really interested in doing mushrooms in order to feel what kind of doors open, have a trip that was my own.

According to Bell, husband Jax Shepard was on hand to oversee, but not participate.

I am very lucky to be married to an ex-drug addict, she joked. Not only did he know where to get the mushrooms he got that really nice, quality, organic, set and setting, beautiful mushroom. And then he babysat me.

Bell said she took her trip on her last birthday. I said, I really would like to experience this. And I dont want to, Im not going to party with it, but I want to know what this feels like. And I want to talk while Im doing it, and I want you to talk to me. And he took me on a walk around the neighbourhood and it was so lovely.

RELATED: Kristen Bell Says Shes Turned On By Dax Shepards Sense Of Humour: The Stupid S**t He Does Just By Being Himself Is So Attractive To Me

One effect the mushrooms had, she revealed, was to make her so enamoured with her own body.

I had gone to the bathroom, I went to pee and I came downstairs wide-eyed and I said, Dax, I had to pee. I felt the sensation of having to pee and all of a sudden this beautiful lady and I was pointing to my legs picked me up. She walked me down the hallway. She sat me down on the toilet. She rolled a little roll of toilet paper for me and just put it on my lap till I was done peeing. Then she wiped me. Then she flushed the toilet and now Im back out here,' she recalled.

But in my head, I had separated this body that had done so much good in my life, that has taken me through happiness and pain and workouts and laziness that I was just like, couldnt stop touching my legs going, Youre so strong. Youre so elegant.

The entire podcast episode can be heard below.

Read more:

Kristen Bell Reveals She Tried Psychedelic Mushrooms To Treat Her Depression - ETCanada.com

Psychedelics have been used for healing purposes for thousands of years, but popular culture is only beginning to understand just how powerful and multifaceted these substances are. This article will explore the past and present of psychedelic medicine, as well as introduce you to Psychable an online resource aimed at helping people find professionals who can support them on their journey with psychedelics.

What is Psychedelic Medicine?

Psychedelic medicine is an emergent field that utilizes naturally occurring or synthetic psychedelic substances as tools for healing and self-improvement.

The Controlled Substances Act prohibited psychedelic use in 1971, crucially limiting research efforts and driving many psychedelic therapists underground or abroad to locations with less stringent laws. However, in the last decade, partly due to tireless advocacy on the part of organizations such as the Multidisciplinary Association for Psychedelic Studies (MAPS), research into psychedelics is seeing a revival.

A limited but promising body of clinical evidence on the safety and efficacy of psychedelic substances such as psilocybin, LSD, ketamine, ayahuasca, and MDMA shows that they may be able to treat various psychological and physical disorders. At higher doses, psychedelics such as LSD may increase neuroplasticity, the ability of our brains to change and adapt.

One survey study even found that psychedelic use is linked to better physical health. Current research supports the idea that psychedelic substances could have powerful healing potential for a variety of conditions, such as PTSD, major depression, anxiety, and substance use disorder.

The potential for psychedelic medicine to successfully treat these disorders is exciting, as many of these conditions are often resistant to conventional treatment, says Jemie Sae Koo, Psychable CEO and Co-Founder.

However, more research is needed in order to determine how to optimize outcomes for patients and what psychedelic therapy protocols are best indicated for specific conditions. Researchers are also investigating psychedelics for applications such as coping with racial trauma, eating disorders, obsessive-compulsive disorder (OCD), and even reducing recidivism.

Additionally, psychedelics can help people to expand their minds in fascinating ways. Many professionals, especially from the tech and business world, report microdosing LSD to solve problems, enhance creativity and improve performance. Some microdosing research suggests that subjective benefits of microdosing may only be the placebo effect rather than the efficacy of the drug explicitly.

Although researchers are cautiously optimistic about psychedelics for mental health conditions, there is not enough clinical evidence to prove that psychedelics can address the problems of the modern world.

Keeping Up with the Current Research and Trends in Psychedelic Medicine

Psychedelics are not a panacea, explains Matt Zemon, Psychable Chief Strategy Officer and Co-Founder. Some people try to fit psychedelic medicine into their existing concept of medicine, typically the western medical paradigm that rests heavily on the use of pharmaceutical interventions or surgical procedures. This may lead to the misunderstanding that psychedelics are potential instant cures for diagnoses. Psychedelics are tools; just like a knife that can be used in service of help or harm.

This oversimplification of psychedelic medicine is one example of the shadow side of psychedelics, a phenomenon receiving more attention recently as global interest and demand increase. Other related issues include accessibility, the overharvesting, and endangerment of peyote and iboga, the complexities of decriminalization efforts, the potential pitfalls of mainstreaming psychedelics, ethical and legal issues, spiritual bypassing, sexual misconduct in psychedelic therapy and psychedelic spaces, and more.

Psychable can help you get informed about everything in the world of psychedelic medicine. They envision a world where the safe, legal and ethical use of psychedelics has transformed global mental health, allowing more people to heal, transform and access their true potential. Psychables mission is to empower individuals seeking the healing properties of psychedelics with practitioners, knowledge, and a safe community that legally supports them.

As the legal landscape continues to shift, Psychable aims to simplify the process of finding experienced professionals who offer legal healing modalities and pre-and post-psychedelic experience support.

Psychable is for service-seekers and practitioners, as well those who are new to learning about psychedelic-assisted therapy. Browse their collection of evidence-based articles, participate in their engaged and passionate online forum, and check out the professional directory powered by ratings and reviews.

Published May 15th, 2021

More:

Psychedelic Medicine Read All About It on Psychable - Influencive

What factors should businesses account for when investing in the production, provision or sale of psychedelics or related services? What are the risks and potential benefits of entering this area now?

In addition to the start-up risks facing psychedelics companies as early-stage pre-revenue companies or as companies with modest revenues, since psychedelics are, and are likely to remain, highly regulated substances, certainty in the application and design of legal and regulatory regimes in which the business operates should be at the forefront of considerations of businesses in the psychedelics industry. This may not be true for all of the activities of a psychedelics business, but in our view should be for a majority of the operations of those businesses. For example, jurisdictions that have legal and regulatory regimes that are in constant flux or that have inequitable or unpredictable results limit the ability of psychedelics companies to, among other things, operate effectively, gain investor confidence, access capital and banking, develop products or deliver services in a timely and cost-effective manner.

In addition, one of the key risks facing many psychedelics is the risk of getting lost in the crowd. In the past 12 months a significant number of psychedelics companies have completed go public transactions and raised capital. Many more have raised substantial amounts of capital and have grown to a significant size, but remain private. Many of these existing companies have similar business plans so a company finding its niche in the market has become that much more challenging. That being said, the psychedelics industry is experiencing a renaissance in the investment community, the medical or health and wellness community and the general public, with substantial areas of opportunity for enterprising psychedelics companies that want to make a meaningful difference through the advancement of ground-breaking therapies.

How would you advise clients in this area to limit their exposure to liability and potential litigation? Do clients in the psychedelics space require protection against multiple types of liability?

In addition to ordinary course business risks, psychedelics companies face risks associated with operating in a nascent, rapidly evolving, yet highly regulated industry. In our experience, these factors, and others, require companies in the psychedelics industry to professionalize their management teams and establish sophisticated processes and views on risk at a much earlier stage that companies operating in other industries. By taking these actions at an earlier stage, psychedelics companies can formulate strategies to identify, weigh and manage risk, to make informed decisions on risk versus reward for the opportunities they consider. As the psychedelics industry continues to develop so does the insurance industry supporting these companies, with an increasing range of insurance products becoming rapidly becoming available.

Read this article:

Canada's Psychedelic Future: a guide to the evolving legal and regulatory landscape and what's next - Lexpert